Ovarian hyperstimulation syndrome: Prevention in IVF and non-IVF treatment

Assisted Reproductive Technologies: Quality and Safety

Volumn , Issue , 2003, Pages 169-180

  Guibert, J ^a   Olivennes, F ^a  

^a Hôpital Cochin ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33646446500     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (55)

1. Enskog A, Henriksson M, Unander M, et al.Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril1999; 71: 808-14
2. Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev1997; 18: 71-106
3. Mathur RS, Jenkins JM. Severe OHSS: patients should be allowed to weigh the morbidity of OHSS against the benefits of parenthood. Hum Reprod1999; 14: 2183-5
4. Knowler WC, Barrett-Connor E, Fowler SE, et al.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N EnglJ Med2002; 346: 393-403
5. Amer SA, Gopalan V Li TC, et al.Long term follow-up of patients with polycystic ovarian syndrome after laparoscopic ovarian drilling: clinical outcome. Hum Reprod2002; 17: 2035-42
6. De Leo V la Marca A, Ditto A, et al.Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril1999; 72: 282-5
7. Morris RS, Karande VC, Dudkiewicz A, et al. Octreotide is not useful for clomiphene citrate resistance in patients with polycystic ovary syndrome but may reduce the likelihood of ovarian hyperstimulation syndrome. Fertil Steril 1999; 71: 452-6
8. Rimington MR, Walker SM, Shaw RW. The use of laparoscopic ovarian electrocautery in preventing cancellation of in-vitro fertilization treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries. Hum Reprod1997; 12: 1443-7
9. Rongieres-Bertrand C, Olivennes F, Righini C, et al. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Hum Reprod1999; 14: 683-8
10. Tan SL, Child TJ. In-vitro maturation of oocytes from unstimulated polycystic ovaries. Reprod Biomed Online2002; 4: 18-23
11. Hughes E, Collins J, Vandekerckhove P Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome. Cochrane Database Syst Rev 2000; 2: CD000087
12. Marci R, Senn A, Dessole S, et al. A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins. Fertil Steril2001; 75: 1131-5
13. El-Sheikh MM, Hussein M, Fouad S, et al.Limited ovarian stimulation (LOS), prevents the recurrence of severe forms of ovarian hyperstimulation syndrome in polycystic ovarian disease. Eur J Obstet Gynecol Reprod Biol2001; 94: 245-9
14. Daya S. Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fertil Steril2002; 77: 711-14
15. The European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod2001; 16: 644-51
16. Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod2002; 17: 874-85
17. Lewit N, Kol S, Manor D, Itskovitz-Eldor J. Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case-control study. Hum Reprod1996; 11: 1399-402
18. Fauser BC, de Jong D, Olivennes F, et al.Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitrofertilization. J Clin Endocrinol Metab2002; 87: 709-15
19. Olivennes F, Cunha-Filho JS, Fanchin R, et al.The use of GnRH antagonists in ovarian stimulation. Hum Reprod Update2002; 8: 279-90
20. Thomas K, Searle T, Quinn A, et al.The value of routine estradiol monitoring in assisted conception cycles. Acta Obstet Gynecol Scand2002; 81: 551-4
21. Anon. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab2001; 86: 2607-18
22. Soliman S, Daya S, Collins J, et al.The role of luteal phase support in infertility treatment: a meta-analysis of randomized trials. Fertil Steril1994; 61: 1068-76
23. Penzias AS. Luteal phase support. Fertil Steril2002; 77: 318-23
24. Mathur RS, Akande AV Keay SD, et al.Distinction between early and late ovarian hyperstimulation syndrome.Fertil Steril2000; 73: 901-7
25. Christin-Maitre S, Rongieres-Bertrand C, Kottler ML, et al.A spontaneous and severe hyperstimulation of the ovaries revealing a gonadotroph adenoma. J Clin Endocrinol Metab1998; 83: 3450-3
26. Balen AH, Braat DD, West C, et al.Cumulative conception and live birth rates after the treatment of anovulatory infertility: safety and efficacy of ovulation induction in 200 patients. Hum Reprod1994; 9: 1563-70
27. Blankstein J, Shalev J, Saadon T, et al. Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles. Fertil Steril1987; 47: 597-602
28. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update2002; 8: 559-77
29. Delvigne A, Rozenberg S. Preventive attitude of physicians to avoid OHSS in IVF patients. Hum Reprod2001; 16: 2491-5
30. Delvigne A, Rozenberg S. A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients. Hum Reprod Update2002; 8: 291-6
31. D'Angelo A, Amso N. ‘Coasting’ (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2002; (3): CD002811
32. Egbase PE, Sharhan MA, Grudzinskas JG. Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study. Hum Reprod1999; 14: 1421-5
33. Sher G, Zouves C, Feinman M, Maassarani G. 'Prolonged coasting': an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization. Hum Reprod1995; 10: 3107-9
34. Benadiva CA, Davis O, Kligman I, et al.Withholding gonadotropin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome. Fertil Steril1997; 67: 724-7
35. Tortoriello DV, McGovern PG, Colon JM, et al. ‘Coasting’ does not adversely affect cycle outcome in a subset of highly responsive in vitro fertilization patients. Fertil Steril1998; 69: 454-60
36. Dhont M, Van der Straeten F, De Sutter P Prevention of severe ovarian hyperstimulation by coasting. Fertil Steril1998; 70: 847-50
37. Lee C, Tummon I, Martin J, et al.Does withholding gonadotrophin administration prevent severe ovarian hyperstimulation syndrome?Hum Reprod1998; 13: 1157-8
38. Fluker MR, Hooper WM, Yuzpe AA. Withholding gonadotropins (‘coasting’) to minimize the risk of ovarian hyperstimulation during superovulation and in vitro fertilization-embryo transfer cycles. Fertil Steril1999; 71: 294-301
39. Waldenström U, Kahn J, Marsk L, Nilsson S. High pregnancy rates and successful prevention of severe ovarian hyperstimulation syndrome by 'prolonged coasting' of very hyperstimulated patients: a multicentre study. Hum Reprod 1999; 14: 294-7
40. Dechaud H, Anahory T, Aligier N, et al.Coasting: a response to excessive ovarian stimulation. Gynecol Obstet Fertil2000; 28: 115-19
41. Ohata Y, Harada T, Ito M, et al.Coasting may reduce the severity of the ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome. Gynecol Obstet Invest2000; 50: 186-8
42. Aboulghar MA, Mansour RT, Serour GI, et al. Reduction of human menopausal gonadotropin dose before coasting prevents severe ovarian hyperstimulation syndrome with minimal cycle cancellation. J Assist Reprod Genet 2000; 17: 298-301
43. Al-Shawaf T, Zosmer A, Hussain S, et al.Prevention of severe ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer: a modified 'coasting' strategy based on ultrasound for identification of highrisk patients. Hum Reprod2001; 16: 24-30
44. Egbase PE, Al-Sharhan M, Grudzinskas JG. 'Early coasting' in patients with polycystic ovarian syndrome is consistent with good clinical outcome. Hum Reprod2002; 17: 1212-16
45. Egbase PE, Makhseed M, Al Sharhan M, Grudzinskas JG. Timed unilateral ovarian follicular aspiration prior to administration of human chorionic gonadotrophin for the prevention of severe ovarian hyperstimulation syndrome in in-vitro fertilization: a prospective randomized study. Hum Reprod1997; 12: 2603-6
46. Tay CC. Use of gonadotrophin-releasing hormone agonists to trigger ovulation. Hum Fertil (Camb)2002; 5: G35-7
47. Orvieto R, Ben-Rafael Z. The immune system in severe ovarian hyperstimulation syndrome. Isr J Med Sci1996; 32: 1180-2
48. Tan SL, Balen A, el Hussein E, et al.The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in vitro fertilization: a prospective randomized study. Fertil Steril1992; 58: 378-83
49. Costabile L, Unfer V Manna C, et al.Use of intramuscular progesterone versus intravenous albumin for the prevention of ovarian hyperstimulation syndrome. Gynecol Obstet Invest2000; 50: 182-5
50. Graf MA, Fischer R, Naether OG, et al.Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydrox-yaethyl starch solution in an in-vitro fertiliza-tion programme. Hum Reprod1997; 12: 2599-602
51. Konig E, Bussen S, Sutter lin M, Steck T. Prophylactic intravenous hydroxyethyl starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, doubleblind and placebo-controlled study. Hum Reprod1998; 13: 2421-4
52. Gökmen O, Ugur M, Ekin M, et al.Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study. Eur J Obstet Gynecol Reprod Biol2001; 96: 187-92
53. Wada I, Matson PL, Troup SA, et al.Outcome of treatment subsequent to the elective cryo-preservation of all embryos from women at risk of the ovarian hyperstimulation syndrome. Hum Reprod1992; 7: 962-6
54. D'Angelo A, Amso NN. Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Hum Reprod2002; 17: 2787-94
55. Endo T, Honnma H, Hayashi T, et al.Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos. Hum Reprod2002; 17: 2548-51